Pfizer Inc. (NYSE:PFE) Stake Lessened by Profund Advisors LLC

Profund Advisors LLC decreased its holdings in shares of Pfizer Inc. (NYSE:PFEGet Rating) by 5.9% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 153,237 shares of the biopharmaceutical company’s stock after selling 9,586 shares during the quarter. Profund Advisors LLC’s holdings in Pfizer were worth $6,706,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently bought and sold shares of the company. Saxon Interests Inc. boosted its holdings in shares of Pfizer by 12.9% during the third quarter. Saxon Interests Inc. now owns 8,309 shares of the biopharmaceutical company’s stock worth $367,000 after purchasing an additional 951 shares during the period. JB Capital LLC grew its holdings in shares of Pfizer by 3.5% during the 2nd quarter. JB Capital LLC now owns 146,908 shares of the biopharmaceutical company’s stock valued at $7,702,000 after acquiring an additional 5,027 shares in the last quarter. Platte River Wealth Advisors LLC increased its stake in shares of Pfizer by 62.8% in the third quarter. Platte River Wealth Advisors LLC now owns 12,717 shares of the biopharmaceutical company’s stock worth $556,000 after acquiring an additional 4,905 shares during the last quarter. Versor Investments LP raised its holdings in shares of Pfizer by 59.7% during the second quarter. Versor Investments LP now owns 68,200 shares of the biopharmaceutical company’s stock worth $3,576,000 after acquiring an additional 25,500 shares in the last quarter. Finally, Foundry Partners LLC grew its stake in Pfizer by 10.0% in the second quarter. Foundry Partners LLC now owns 485,705 shares of the biopharmaceutical company’s stock valued at $25,466,000 after purchasing an additional 44,260 shares in the last quarter. 67.62% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

PFE has been the subject of a number of recent research reports. Barclays raised their price target on Pfizer from $44.00 to $49.00 and gave the stock an “equal weight” rating in a research note on Wednesday, November 2nd. StockNews.com initiated coverage on shares of Pfizer in a research note on Wednesday, October 12th. They issued a “strong-buy” rating for the company. Morgan Stanley upped their price target on Pfizer from $51.00 to $53.00 and gave the stock an “equal weight” rating in a research note on Wednesday, December 14th. Wells Fargo & Company downgraded Pfizer from an “overweight” rating to an “equal weight” rating and cut their price objective for the company from $54.00 to $50.00 in a research note on Tuesday, January 17th. Finally, JPMorgan Chase & Co. set a $50.00 target price on Pfizer in a research report on Wednesday, January 18th. Seven analysts have rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $53.00.

Pfizer Trading Down 0.1 %

PFE traded down $0.06 during midday trading on Wednesday, reaching $44.65. 4,226,376 shares of the company were exchanged, compared to its average volume of 23,110,918. The company has a debt-to-equity ratio of 0.35, a quick ratio of 1.37 and a current ratio of 1.59. The stock has a market capitalization of $250.63 billion, a P/E ratio of 8.60, a PEG ratio of 1.11 and a beta of 0.67. The stock’s 50-day simple moving average is $49.68 and its 200 day simple moving average is $48.06. Pfizer Inc. has a one year low of $41.44 and a one year high of $56.32.

Pfizer (NYSE:PFEGet Rating) last released its quarterly earnings results on Tuesday, November 1st. The biopharmaceutical company reported $1.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.47 by $0.31. The firm had revenue of $22.64 billion for the quarter, compared to the consensus estimate of $21.04 billion. Pfizer had a return on equity of 43.95% and a net margin of 29.81%. As a group, analysts forecast that Pfizer Inc. will post 6.47 earnings per share for the current fiscal year.

Pfizer Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 3rd. Shareholders of record on Friday, January 27th will be given a dividend of $0.41 per share. The ex-dividend date of this dividend is Thursday, January 26th. This is a boost from Pfizer’s previous quarterly dividend of $0.40. This represents a $1.64 annualized dividend and a yield of 3.67%. Pfizer’s payout ratio is 30.77%.

Pfizer Profile

(Get Rating)

Pfizer Inc is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.

Read More

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFEGet Rating).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.